The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety, dose tolerance, pharmacokinetics and pharmacodynamics study of CPX-POM in patients with advanced solid tumors.
 
Scott James Weir
Research Funding - CicloMed (Inst)
Patents, Royalties, Other Intellectual Property - Co-Inventor on issued Ciclopirox Prodrug composition-of-matter and methods-of-use patents
 
Robyn Wood
Research Funding - CicloMed (Inst)
 
Tammy Ham
Employment - CicloMed
Leadership - CicloMed
Stock and Other Ownership Interests - CicloMed
Patents, Royalties, Other Intellectual Property - CicloMed
 
Rashida Challenger
Employment - Cmed
 
Prabhu Ramamoorthy
Research Funding - CicloMed (Inst)
 
Greg Reed
No Relationships to Disclose
 
Michael Jay Baltezor
Employment - CritiTech
Patents, Royalties, Other Intellectual Property - Inventor on multiple patents that are pending and granted for CritiTech, Inc.
Travel, Accommodations, Expenses - CritiTech
 
Roy A. Jensen
No Relationships to Disclose
 
John Arthur Taylor
Research Funding - CicloMed (Inst)
 
Shrikant Anant
Research Funding - CicloMed (Inst)
 
Michael Dalton
Employment - The Gnomon Group
Leadership - The Gnomon Group
Stock and Other Ownership Interests - The Gnomon Group
 
Michael J McKenna
No Relationships to Disclose
 
Valentina Zhukova-Harrill
Employment - Cmed
Leadership - Cmed
 
William McCulloch
Employment - 3-V Biosciences; CicloMed
Leadership - 3-V Biosciences
Stock and Other Ownership Interests - 3-V Biosciences
Consulting or Advisory Role - CicloMed
Patents, Royalties, Other Intellectual Property - Issued patents relating to romidepsin (Istodax(R)) assigned to Celgene, Inc. No financial interest.
 
Howard A. Burris
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); FORMA Therapeutics (Inst); Janssen (Inst); MedImmune (Inst); Mersana (Inst); Novartis (Inst); Roche/Genentech (Inst); TG Therapeutics (Inst)
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PTC Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); TG Therapeutics (Inst); Valent Technologies (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - Novartis